PFE.DE

Pfizer Inc. [PFE.DE] Stock Forecast

Q: What is Pfizer Inc. stock symbol ?

Pfizer Inc. is a US stock, located in New york of Ny and trading under the symbol PFE.DE

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PFE.DE Stock Summary

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

PFE.DE has less than 1 year of cash runway

Top 10 Correlated ETFs

PFE.DE

Top 10 Correlated Stocks

PFE.DE

In the News

PFE.DE Financial details

Company Rating

Buy

Market Cap

138.8B

Income

2.15B

Revenue

58.5B

Book val./share

15.91

Cash/share

2.27

Dividend

1.64

Dividend %

5.56%

Employees

88K

Optionable

Shortable

Yes

Earnings

30 Apr 2024

P/E

15.89

Forward P/E

PEG

-1.7

P/S

2.43

P/B

1.72

P/C

10.63

P/FCF

20.37

Quick Ratio

1.9

Current Ratio

2.38

Debt / Equity

0.8

LT Debt / Equity

0.68

EPS (TTM)

0.37

EPS next Y

EPS next Q

EPS this Y

-93.25%

EPS next Y

EPS next 5Y

EPS last 5Y

-33.49%

Revenue last 5Y

2.48%

Revenue Q/Q

7.69%

EPS Q/Q

42.86%

SMA20

-7.69%

SMA50

-4%

SMA100

-14.29%

Inst Own

Inst Trans

ROA

ROE

11%

ROC

0.08%

Gross Margin

61%

Oper. Margin

22%

Profit Margin

15%

Payout

88%

Shs Outstand

Shs Float

Target Price

52W Range

23.65-37.8

52W High

-34.77%

52W Low

+4.93%

RSI

Rel Volume

0.38

Avg Volume

103.64K

Volume

39.81K

Perf Week

-1.53%

Perf Month

-3.46%

Perf Quarter

-15.32%

Perf Half Y

-22.02%

Beta

0.572

Volatility

0.25%, 0.63%

Prev Close

1.24%

Price

24.135

Change

1.19%

PFE.DE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	9.29	7.54	14.51	18.02	10.37
Net income per share	2.92	1.26	3.92	5.63	0.38
Operating cash flow per share	2.26	2.59	5.82	5.26	1.54
Free cash flow per share	1.79	2.09	5.33	4.67	0.85
Cash per share	1.77	2.2	5.55	4.08	2.25
Book value per share	11.34	11.38	13.78	17.18	15.77
Tangible book value per share	-5.49	-2.62	0.56	0.21	-7.69
Share holders equity per share	11.34	11.38	13.78	17.18	15.77
Interest debt per share	9.65	7.15	6.84	6.48	12.95
Market cap	207.31B	206.62B	323.44B	284.61B	162.86B
Enterprise value	258.15B	243.11B	358.49B	319.06B	230.86B
P/E ratio	12.74	29.43	14.72	9.07	76.86
Price to sales ratio	4.01	4.93	3.98	2.84	2.78
POCF ratio	16.47	14.35	9.93	9.72	18.72
PFCF ratio	20.74	17.79	10.83	10.93	33.98
P/B Ratio	3.28	3.27	4.19	2.98	1.83
PTB ratio	3.28	3.27	4.19	2.98	1.83
EV to sales	4.99	5.8	4.41	3.18	3.95
Enterprise value over EBITDA	13.07	17.28	12.56	7.31	15.98
EV to operating cash flow	20.51	16.88	11	10.9	26.54
EV to free cash flow	25.83	20.94	12	12.26	48.17
Earnings yield	0.08	0.03	0.07	0.11	0.01
Free cash flow yield	0.05	0.06	0.09	0.09	0.03
Debt to equity	0.83	0.61	0.48	0.36	0.8
Debt to assets	0.31	0.25	0.2	0.18	0.31
Net debt to EBITDA	2.57	2.59	1.23	0.79	4.71
Current ratio	0.88	1.35	1.4	1.22	0.91
Interest coverage	9.62	7.34	19.24	32.33	2.38
Income quality	0.77	2.05	1.45	0.93	4.01
Dividend Yield	0.04	0.04	0.03	0.03	0.06
Payout ratio	0.49	1.2	0.4	0.29	4.36
Sales general and administrative to revenue	0.23	0.23	0.13	0.11	0.17
Research and developement to revenue	0.17	0.22	0.17	0.11	0.18
Intangibles to total assets	0.56	0.51	0.41	0.48	0.59
Capex to operating cash flow	-0.21	-0.19	-0.08	-0.11	-0.45
Capex to revenue	-0.05	-0.07	-0.03	-0.03	-0.07
Capex to depreciation	-0.43	-0.58	-0.52	-0.64	-0.62
Stock based compensation to revenue	0.01	0.02	0.01	0.01	0.01
Graham number	27.3	17.99	34.89	46.66	11.54
ROIC	0.12	0.1	0.2	0.28	0.07
Return on tangible assets	0.22	0.09	0.21	0.31	0.02
Graham Net	-14.55	-11.9	-10.11	-11.34	-19.15
Working capital	-4.5B	9.15B	17.02B	9.12B	-4.46B
Tangible asset value	-30.58B	-14.58B	3.11B	1.17B	-43.4B
Net current asset value	-71.24B	-55.69B	-44.32B	-50.03B	-93.88B
Invested capital	0.83	0.61	0.48	0.36	0.8
Average receivables	11.73B	11.63B	13.47B	15.14B	14.84B
Average payables	4.45B	4.26B	4.94B	6.19B	6.76B
Average inventory	7.9B	8.16B	8.55B	9.02B	9.59B
Days sales outstanding	85.12	97.49	70.7	52.86	94.56
Days payables outstanding	150.73	180.95	66.06	72.36	98.15
Days of inventory on hand	295.85	337.87	107.28	95.45	149.03
Receivables turnover	4.29	3.74	5.16	6.91	3.86
Payables turnover	2.42	2.02	5.53	5.04	3.72
Inventory turnover	1.23	1.08	3.4	3.82	2.45
ROE	0.26	0.11	0.28	0.33	0.02
Capex per share	-0.47	-0.5	-0.48	-0.58	-0.69

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.33	3.24	2.26	2.34	2.55
Net income per share	0.89	0.98	0.41	-0.42	-0.6
Operating cash flow per share	1.53	0.22	-0.21	0.61	0.94
Free cash flow per share	1.35	0.01	-0.38	0.47	0.75
Cash per share	4.05	3.54	7.93	7.83	2.27
Book value per share	17.04	17.92	17.54	17.17	15.91
Tangible book value per share	0.21	1.38	1.12	0.97	-7.75
Share holders equity per share	17.04	17.92	17.54	17.17	15.91
Interest debt per share	6.27	6.26	11.66	11.39	12.78
Market cap	286.96B	231.25B	207.09B	187.62B	161.52B
Enterprise value	321.41B	264.01B	269.8B	248.07B	229.52B
P/E ratio	14.37	10.43	22.25	-19.69	-12.08
Price to sales ratio	11.81	12.65	16.26	14.18	11.34
POCF ratio	33.44	190.8	-171.43	54.29	30.83
PFCF ratio	37.85	3.17K	-97.59	70.91	38.49
P/B Ratio	3	2.29	2.09	1.94	1.81
PTB ratio	3	2.29	2.09	1.94	1.81
EV to sales	13.23	14.44	21.19	18.75	16.11
Enterprise value over EBITDA	42.5	31.44	64.08	-308.93	-42.08
EV to operating cash flow	37.45	217.83	-223.34	71.78	43.8
EV to free cash flow	42.4	3.62K	-127.14	93.75	54.7
Earnings yield	0.02	0.02	0.01	-0.01	-0.02
Free cash flow yield	0.03	0	-0.01	0.01	0.03
Debt to equity	0.36	0.35	0.66	0.66	0.8
Debt to assets	0.18	0.18	0.3	0.3	0.31
Net debt to EBITDA	4.56	3.9	14.9	-75.28	-12.47
Current ratio	1.22	1.37	2.12	2.38	0.91
Interest coverage	20.55	22.93	5.96	-2.85	-10.35
Income quality	1.72	0.22	-0.52	-1.45	-1.57
Dividend Yield	0.01	0.01	0.01	0.01	0.01
Payout ratio	0.45	0.42	0.99	-0.97	-0.69
Sales general and administrative to revenue	0.08	0	0	0	0.03
Research and developement to revenue	0.15	0.14	0.21	0.2	0.19
Intangibles to total assets	0.48	0.48	0.42	0.43	0.59
Capex to operating cash flow	-0.12	-0.94	0.76	-0.23	-0.2
Capex to revenue	-0.04	-0.06	-0.07	-0.06	-0.07
Capex to depreciation	-0.66	-0.77	-0.58	-0.52	-0.63
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	18.46	19.92	12.75	12.77	14.62
ROIC	0.05	0.05	0.02	-0.01	-0.05
Return on tangible assets	0.05	0.05	0.02	-0.02	-0.04
Graham Net	-11.25	-10.3	-10.78	-10.15	-19.31
Working capital	9.12B	13.52B	38.7B	42.88B	-4.46B
Tangible asset value	1.17B	7.76B	6.31B	5.45B	-43.4B
Net current asset value	-50.03B	-44.3B	-47.53B	-43.81B	-93.88B
Invested capital	0.36	0.35	0.66	0.66	0.8
Average receivables	16.57B	14.99B	14.44B	14.21B	15.08B
Average payables	6.54B	6.47B	6.1B	5.71B	6.02B
Average inventory	9.25B	9.26B	9.93B	10.26B	10.2B
Days sales outstanding	53.83	76.03	94.88	102.05	95.72
Days payables outstanding	63.52	112.79	169.07	51.83	46.05
Days of inventory on hand	83.78	175.74	286.65	99.08	69.93
Receivables turnover	1.67	1.18	0.95	0.88	0.94
Payables turnover	1.42	0.8	0.53	1.74	1.95
Inventory turnover	1.07	0.51	0.31	0.91	1.29
ROE	0.05	0.05	0.02	-0.02	-0.04
Capex per share	-0.18	-0.2	-0.16	-0.14	-0.19

PFE.DE Dividend History

PFE.DE Frequently Asked Questions

What is Pfizer Inc. stock symbol ?

Pfizer Inc. is a US stock , located in New york of Ny and trading under the symbol PFE.DE

What is Pfizer Inc. stock quote today ?

Pfizer Inc. stock price is $24.135 today.

Is Pfizer Inc. stock public?

Yes, Pfizer Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 103.64K
Market Capitalization 138.8B
Employee 88K
CEO Dr. Albert Bourla D.V.M., Ph.D.
Headquarters New York,NY,US
IPO Date 2007-12-28
Website https://www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.